069620 — Daewoong Pharma Balance Sheet
0.000.00%
- KR₩2tn
- KR₩3tn
- KR₩1tn
- 62
- 35
- 94
- 74
Annual balance sheet for Daewoong Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 177,120 | 173,734 | 140,651 | 137,685 | 116,347 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 147,652 | 159,635 | 179,243 | 177,954 | 212,456 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 528,351 | 520,401 | 548,968 | 574,824 | 612,792 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 393,690 | 395,866 | 440,890 | 521,919 | 675,666 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,366,908 | 1,410,687 | 1,563,341 | 1,770,311 | 1,976,977 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 326,750 | 460,660 | 472,831 | 667,117 | 629,416 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 815,914 | 841,156 | 955,323 | 1,003,008 | 1,182,403 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 550,994 | 569,531 | 608,017 | 767,303 | 794,574 |
| Total Liabilities & Shareholders' Equity | 1,366,908 | 1,410,687 | 1,563,341 | 1,770,311 | 1,976,977 |
| Total Common Shares Outstanding |